Back to Search Start Over

PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.

Authors :
Layman, Rachel M.
Arun, Banu
Source :
Cancer Journal; Jan/Feb2021, Vol. 27 Issue 1, p67-75, 9p
Publication Year :
2021

Abstract

<bold>Abstract: </bold>Poly(ADP-ribose) polymerase (PARP) is involved in single-strand DNA break base excision repair. PARP inhibition causes synthetic lethality in breast cancers associated with germline BRCA1 and BRCA2 mutations and is routinely used in clinical practice for metastatic breast cancer. Breast cancers with homologous recombination deficiency or BRCAness, most commonly triple-negative breast cancers, may also benefit. Currently, PARP inhibitor use for triple-negative breast cancer with wild-type BRCA does not have definitive efficacy; however, this is an area of active research. Further clinical and translational data may identify additional patient populations that will benefit from PARP inhibitor therapy. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
15289117
Volume :
27
Issue :
1
Database :
Supplemental Index
Journal :
Cancer Journal
Publication Type :
Academic Journal
Accession number :
148716558
Full Text :
https://doi.org/10.1097/PPO.0000000000000499